James M Luther1. 1. aDivision of Clinical Pharmacology bDivision of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Abstract
PURPOSE OF REVIEW: This review will highlight recent developments in mineralocorticoid receptor research which impact aldosterone-associated vascular and cardiometabolic dysfunction. RECENT FINDINGS: The mineralocorticoid receptor is also expressed in vascular smooth muscle and vascular endothelium, and contributes to vascular function and remodeling. Adipocyte-derived leptin stimulates aldosterone secretion, which may explain the observed link between obesity and hyperaldosteronism. Adipocyte mineralocorticoid receptor overexpression produces systemic changes consistent with metabolic syndrome. Ongoing studies with novel nonsteroidal mineralocorticoid receptor antagonists may provide a novel treatment for diabetic nephropathy and heart failure in patients with chronic kidney disease, with reduced risk of hyperkalemia. SUMMARY: Ongoing research continues to demonstrate novel roles of the vascular and adipocyte mineralocorticoid receptor function, which may explain the beneficial metabolic and vascular benefits of mineralocorticoid receptor antagonists.
PURPOSE OF REVIEW: This review will highlight recent developments in mineralocorticoid receptor research which impact aldosterone-associated vascular and cardiometabolic dysfunction. RECENT FINDINGS: The mineralocorticoid receptor is also expressed in vascular smooth muscle and vascular endothelium, and contributes to vascular function and remodeling. Adipocyte-derived leptin stimulates aldosterone secretion, which may explain the observed link between obesity and hyperaldosteronism. Adipocyte mineralocorticoid receptor overexpression produces systemic changes consistent with metabolic syndrome. Ongoing studies with novel nonsteroidal mineralocorticoid receptor antagonists may provide a novel treatment for diabetic nephropathy and heart failure in patients with chronic kidney disease, with reduced risk of hyperkalemia. SUMMARY: Ongoing research continues to demonstrate novel roles of the vascular and adipocyte mineralocorticoid receptor function, which may explain the beneficial metabolic and vascular benefits of mineralocorticoid receptor antagonists.
Authors: Anton H van den Meiracker; Rini Ga Baggen; Sacha Pauli; Anouk Lindemans; Arnold G Vulto; Don Poldermans; Frans Boomsma Journal: J Hypertens Date: 2006-11 Impact factor: 4.844
Authors: Anette Fiebeler; Jürg Nussberger; Erdenechimeg Shagdarsuren; Song Rong; Georg Hilfenhaus; Nidal Al-Saadi; Ralf Dechend; Maren Wellner; Silke Meiners; Christiane Maser-Gluth; Arco Y Jeng; Randy L Webb; Friedrich C Luft; Dominik N Muller Journal: Circulation Date: 2005-06-06 Impact factor: 29.690
Authors: Christine Guo; Vincent Ricchiuti; Bill Q Lian; Tham M Yao; Patricia Coutinho; José R Romero; Jianmin Li; Gordon H Williams; Gail K Adler Journal: Circulation Date: 2008-04-21 Impact factor: 29.690
Authors: Erik Ingelsson; Michael J Pencina; Geoffrey H Tofler; Emelia J Benjamin; Katherine J Lanier; Paul F Jacques; Caroline S Fox; James B Meigs; Daniel Levy; Martin G Larson; Jacob Selhub; Ralph B D'Agostino; Thomas J Wang; Ramachandran S Vasan Journal: Circulation Date: 2007-08-13 Impact factor: 29.690
Authors: Justin P Zachariah; Yunfei Wang; Jane W Newburger; Sarah D deFerranti; Gary F Mitchell; Ramachandran S Vasan Journal: J Am Heart Assoc Date: 2021-03-01 Impact factor: 5.501
Authors: Mateusz Wierdak; Grzegorz Sokołowski; Michał Natkaniec; Karolina Morawiec-Sławek; Piotr Małczak; Piotr Major; Alicja Hubalewska-Dydejczyk; Andrzej Budzyński; Michał Pędziwiatr Journal: Wideochir Inne Tech Maloinwazyjne Date: 2018-04-03 Impact factor: 1.195